diagnost tool
price close busi octob
leader comprehens liquid
biopsi profil cancer patient offer suit
test includ flagship test across
area like therapi select advanc initi
recurr monitor later earli detect
cancer lunar program
guardant initi enrol larg eclips
close guardant announc initi enrol larg eclips
prospect observ colon cancer pivot trial set motion goal
launch first mani screen test news line manag
expect import step toward goal obtain fda approv
launch first screen test risk ahead gh target blood-bas
screen test fda-clear cover medicar includ uspstf
screen guidelin view latter two biggest risk unclear
time beyond colon cancer guardant plan develop screen test lung breast
ovarian cancer least view reiter buy pt
announc enrol first patient eclips prospect colon cancer studi
announc afternoon initi larg eclips
evalu ctdna lunar test averag patient screen episod pivot
trial multi-sit observ studi evalu perform
blood test detect colorect cancer average-risk adult compar
colonoscopi trial expect enrol patient age bit differ
exass landmark deep-c studi enrol patient age
estim time fda approv medicar reimburs guardant expect
primari endpoint eclips trial read januari guardant pursu
attract fda/cm parallel review pathway estim gh assay could
obtain fda approv reimburs earli januari view
uspstf guidelin prevent servic task forc uspstf
volunt group physician typic meet everi year examin
peer-review data determin screen guidelin expect uspstf publish
revis screen guidelin thu think highli
unlik gh could get guidelin thu may need wait
said think possibl gh could get fda/cm parallel review program
launch test medicar popul get uspstf guidelin
refer took year month time enrol
first patient deep-c studi new england journal medicin public
potenti competitor like freenom grail thrive appear
similar boat gh relat get uspstf screen guidelin
build promis earli data guardant abstract demonstr promis
though preliminari data small data set larg prospect
studi gh demonstr sensit specif sensit
stage respect estim
bogey fda-clear early-stag cancer test better sensit
better specif across cohort patient real world
asymptomat popul demonstr sensit specif
though look rais bar cologuard initi expect read
next week acg titl novel multi-target stool dna marker panel yield highli
accur detect colorect cancer premalign neoplasia
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
liquid biopsi market leader offer
flagship test use therapi select late stage cancer patient
guardant omni test pharma compani time compani look develop
test across cancer continuum includ therapi select recurr monitor
eventu screen initi coverag guardant year
report found proprietari interview medic oncologist use
found
model revenu estim unchang revenu
model revenu growth rate
model gross margin may
prove conserv model profit though model assum
neglig product revenu screen test year believ
price target pt gh use premium multipl revenu
estim million discount back year discount rate use
recent oper result materi exceed expect report
guardant deliv monster beat-and-rais thank strong beat across
busi revenu growth clock y/i beat clinic test
pharma volum posit surpris surg
gross margin came rang seven quarter ago
note guardant busi power oper leverag premium price
pharma help like guardant long-term strateg
think execut global vision across cancer late-stag therapi select
cancer monitor time early-stag cancer screen
beat recal revenu y/i crush
y/i /street gh report test clinic custom y/i
test biopharmaceut custom y/i major step-funct
increas gross margin outstand point y/i basi
far net loss per share better
gh drove strength across guardantomni
pharmaceut partner addit gh benefit recent near doubl
sale forc peopl wake nile studi seek usher
paradigm blood-first test away tissu
guid recal earn call gh rais revenue guid
recal gh rais revenu guid
call y/i y/i gh
demonstr strength result robust pharma work came gh
expect level growth repeat due time work
like result step-down revenu growth gross margin
fda submiss gh indic plan submit fda given
breakthrough devic design think fda approv like hit around
pan-canc decis gh expect pan-canc medicar coverag draft decis
turn final later year may see benefit certainli
colon cancer screen guardant enrol first patient eclips
prospect colon cancer studi prospect observ studi seek enrol
least patient gh excit potenti though acknowledg risk
note expect studi cost proce last capit
rais level view small given potenti gh feel good
incorpor epigenom marker nucleosom fragmentom develop
test fda-clear cover medicar includ uspstf screen
guidelin view latter two biggest risk unclear time
time beyond colon cancer plan develop screen test
lung breast ovarian cancer least view awar
compani lock assay thu believ possibl gh could improv
upon data demonstr
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research iii best author analyst
knowledg she/h receipt materi non-publ inform issuer
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin octob et
date time product octob et
pt gh use premium multipl revenu estim million discount back year
pt use multipl revenu estim billion discount back year discount rate
price target appli multipl adj ep estim
risk achiev target price valuat
premium valuat gh trade premium multipl rel mani diagnost compani given gh best class liquid
biopsi portfolio huge believ valuat warrant bad news regulatori reimburs time product
launch shortfal financi could result lower move stock
risk obtain fda approv flagship test pan-canc label current ldt
gh take assay fda expedit access pathway via breakthrough devic design eap design
expect give prioriti review access senior fda offici doesnt guarante approv guardant view fda approv
signific mileston need facilit commerci adopt extend approv timelin would pose risk
risk obtain pan-canc medicar coverag today gh medicar coverag nsclc guardant
expect obtain pan-canc medicar coverag base expect fda approv guardant expect nation
coverag determin ncd test delay obtain pan-canc coverag would limit compani opportun
risk obtain fda approv guardantomni guardant recent launch guardant omni research use intend
take guardantomni fda obtain fda approv delay time rel expect could limit
compani opportun revenu
manag execut risk given technic natur develop liquid biopsi gh commerci success depend
manag abil launch new panel secur addit reimburs regulatori new label win
provid guidanc shortfal rel guid mark materi risk
risk launch commerci compani largest market opportun gh peg market opportun
high risk individu huge opportun primarili requir strong data gh releas promis pilot
data rel small sampl size guardant experi setback poor result delay/cancel launch
gh growth potenti would significantli reduc
competit guardant compet directli compani provid comprehens genom profil therapi select
foundat medicin roch think guardant like compet recurr monitoring/residu diseas
market among other guardant may compet screen diagnost compani includ
colorect cancer screen possibl grail launch
diagnost tool
reimburs risk end cover live think fda approv like drive
broader payor adopt larg health insur aet other current coverag decis guardant
fail increas reimburs coverag would limit opportun
risk relat intern expans guardant offer test countri outsid establish
amea softbank facilit expans asia middl east africa engag clinic trial work japan lack
compel data regulatori setback could delay expans plan ou addit guardant could struggl facilit adopt
emerg market due pricing/reimburs test
relianc sole supplier guardant reli heavili sole sequenc provid gh activ suppli agreement
decemb automat renew thereaft contract either parti option opt agreement
notic year advanc opt gh may struggl find replac sequenc meet perform
risk relat oper larg grow lab san francisco bay area home earthquak san francisco bay area
prone earthquak larg earthquak could interrupt lab oper compani lab headquart redwood citi ca
risk model includ number new physician add per quarter physician re-ord rate level
 spend cologuard re-ord year first cologuard user due re-screen
pama pama establish medicar price base weight median commerci payor rate pama present
expect go effect januari though time could push opinion view risk
small none given view pama rate like remain similar present medicar rate
competit mani compani develop colorect screen modal particularli blood test liquid biopsi
compani includ grail name three test like fobt fecal occult blood test
fecal immunochem test use year mani new test offer cancer detect uncertain competit
develop test proven pre-canc claim
reimburs pursu health plan coverag privat commerci payor assur health plan
elect cover cologuard uncertainti price might reimburs test
note typic medic technolog risk risk includ commerci execut sale market team regulatori risk
fda potenti product recal patent infring product liabil lawsuit anti-trust litig
commerci execut season ebb flow involv direct sell primari care physician gi
assur abl meet exceed guidanc provid quarter-to-quart
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
diagnost tool
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
